The Norwegian Addiction, Pain and Trauma Study
NCT04908410 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1650
Last updated 2024-12-27
Summary
In populations with substance use disorders (SUD), there is a high prevalence of chronic pain with various underlying causes. Chronic pain can complicate the treatment of SUD and lead to poorer treatment outcomes. There is a need for a better understanding of the connections and interactions between chronic pain and substance use and dependence.
Further, there is a high prevalence of chronic pain among patients with post-traumatic stress disorder (PTSD). As there is an overlap between populations with SUD and PTSD, taking potentially traumatizing life-experiences and post-traumatic stress symptoms into account can provide a better understanding of chronic pain in populations with SUD.
The Nor-APT study is a cross-sectional study, recruiting from outpatient and inpatient substance use treatment centres connected to four hospitals. Participants complete a questionnaire about substance/medication use, pain and how pain affect function, stressful life events and post-traumatic stress symptoms. Patients can consent to self-reported data being linked to retrospective and prospective longitudinal data from national demographic and health registries.
The purpose of the study is to contribute to a better understanding and treatment of chronic pain among people with substance use disorders (SUD), and to contribute to the understanding of co-occurring substance use, chronic pain and post-traumatic stress symptoms.
The over-arching research aims are to:
I. Describe the prevalence and characteristics of pain for people in need of treatment for substance/medication use/dependence.
II. Describe how the pain affects physical and emotional functioning, and subjective quality of life.
III. Explore any connections between substance/medication use and pain, both what came first and any ways substance/medication use and pain affect each other.
IV. Explore the connection between chronic pain, potentially traumatizing life events and post-traumatic stress symptoms.
V. Explore how treatments received and how treatment affects outcomes.
In addition, we will explore whether participants' experiences can be categorized into typical trajectories for how substance use, chronic pain and stressful life events occur and develop over the life span.
Conditions
- Chronic Pain
- Post-traumatic Stress Disorder
- Substance Use Disorders
Sponsors & Collaborators
-
Oslo University Hospital
collaborator OTHER -
Norwegian Center for Violence and Traumatic Stress Studies
collaborator OTHER -
The Hospital of Vestfold
collaborator OTHER -
Sykehuset Telemark
collaborator OTHER_GOV -
University Hospital, Akershus
lead OTHER
Principal Investigators
-
Ingeborg Skjærvø, PhD · Ingeborg Skjærvø
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-03-23
- Primary Completion
- 2024-06-02
- Completion
- 2030-12-31
Countries
- Norway
Study Locations
More Related Trials
-
Personality and Drug Use (PDU)
NCT05180149 ·Status: WITHDRAWN
-
Evaluation of the Management of Tramadol Use Disorders
NCT04550754 ·Status: COMPLETED
-
Changes in Striatal [11C]ORM-13070 Binding Elicited by Changing Levels of Endogenous Noradrenaline
NCT01794975 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Opioid Modulation of the Effect of Alcohol on the Dopaminergic Reward System
NCT03854942 ·Status: TERMINATED ·Phase: PHASE1
-
Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder
NCT03143855 ·Status: COMPLETED ·Phase: PHASE1
-
Neuromodulation and Cognitive Training in Opioid Use Disorder
NCT03773523 ·Status: RECRUITING ·Phase: NA
-
Effects of Pharmacological Stress and rTMS on Executive Function in Opioid Use Disorder
NCT04231708 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Characteristic of Drug Users Chronic Wound
NCT03608384 ·Status: COMPLETED
-
Naltrexone in Borderline Personality Disorder
NCT00124839 ·Status: TERMINATED ·Phase: PHASE3
-
Voluntary Drug Poisoning by Psychoactive Molecules: Identify Cognitive Markers
NCT03481192 ·Status: UNKNOWN ·Phase: NA
-
Personality and Drug Use
NCT05516823 ·Status: UNKNOWN
-
Dopamine and Opioid Receptor Antagonists Reduce Cue-induced Reward Responding and Reward Impulsivity
NCT02557984 ·Status: COMPLETED ·Phase: NA
-
PHAST: Physical Activity in Substitution Therapy
NCT02309021 ·Status: COMPLETED ·Phase: NA
-
New Psychoactive Substances in Intoxicated Patients During the Winter Activities
NCT04155281 ·Status: COMPLETED
-
Methamphetamine and Troriluzole
NCT06989853 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
GHB Poisoning and Poisoning Induced by Others
NCT03651778 ·Status: COMPLETED
-
Mapping Ibogaine Neural Dynamics in Opioid Use Disorder
NCT07226570 ·Status: RECRUITING
-
Adverse Drug Events at Emergency Department
NCT03442010 ·Status: COMPLETED
-
Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED
NCT02643355 ·Status: COMPLETED ·Phase: NA
-
Identification of Psychoactive Substance Users in Young Adults (16 to 25 Years Old) Visiting the Emergency Department
NCT04173546 ·Status: COMPLETED
-
Differential Acute Tolerance Development to Effects of Nitrous Oxide - 7
NCT00000255 ·Status: COMPLETED ·Phase: PHASE2
-
Psychiatric Disorders in Addiction - Interest of Screening and Influence on Relapse
NCT07023419 ·Status: RECRUITING
-
Neurobiology of Opioid Dependence: 1 - 1
NCT00000192 ·Status: WITHDRAWN ·Phase: PHASE2
-
Development of a Valid Test Battery for Assessing Driving Ability When Influenced by Drugs.
NCT00967421 ·Status: COMPLETED ·Phase: NA
-
Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment
NCT04343339 ·Status: COMPLETED